Substance / Medication

Quazepam

Overview

Active Ingredient
quazepam
RxNorm CUI
35185

Indications

Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often

Labeler: Atland Pharmaceuticals, LLCUpdated: 2025-10-23T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

5.1 7 [see Warnings and Precautions (), Drug Interactions ()] Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Lim

Contraindications

When this intervention should not be used

Quazepam Tablets are contraindicated in patients with known hypersensitivity to quazepam or other benzodiazepines. Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of Quazepam Tablets. Some patients have had ad

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Drug interaction between St John's Wort and quazepam.
Kawaguchi Atsuhiro, Ohmori Masami, Tsuruoka Shu-Ichi et al. · Br J Clin Pharmacol · 2004
PMID: 15373933TrialFull text (PMC)
Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.
Fukasawa Takashi, Yasui-Furukori Norio, Aoshima Toshiaki et al. · Ther Drug Monit · 2004
PMID: 15385836Trial
Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.
Kato Kimiyasu, Yasui-Furukori Norio, Fukasawa Takashi et al. · Ther Drug Monit · 2003
PMID: 12883232Trial
Effects of foods on the pharmacokinetics and clinical efficacy of quazepam.
Kim Youngho, Morikawa Masayuki, Ohsawa Hiroyoshi et al. · Nihon Shinkei Seishin Yakurigaku Zasshi · 2003
PMID: 14653226Trial
Interaction study between fluvoxamine and quazepam.
Kanda Hideto, Yasui-Furukori Norio, Fukasawa Takashi et al. · J Clin Pharmacol · 2003
PMID: 14615476Trial
Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.
Yasui-Furukori Norio, Takahata Takenori, Kondo Tsuyoshi et al. · Br J Clin Pharmacol · 2003
PMID: 12680887TrialFull text (PMC)
Comparison of hangover effects among triazolam, flunitrazepam and quazepam in healthy subjects: a preliminary report.
Takahashi Taro, Okajima Yuka, Otsubo Tempei et al. · Psychiatry Clin Neurosci · 2003
PMID: 12753571Trial
Effect of dietary fat content in meals on pharmacokinetics of quazepam.
Yasui-Furukori Norio, Kondo Tsuyoshi, Takahata Takenori et al. · J Clin Pharmacol · 2002
PMID: 12463728Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Quazepam (substance)
SNOMED CT
108391004
UMLS CUI
C0072828
RxNorm CUI
35185
Labeler
Atland Pharmaceuticals, LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.